Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase Ib Study of BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer

Summary

The purpose of this phase I trial is to evaluate the maximum tolerated dose and safety of the ERK inhibitor BVD-523 at the recommended phase II dose in combination with nab-paclitaxel plus gemcitabine in patients with newly diagnosed metastatic pancreatic cancer.

General Information

NCT#: NCT02608229
Study ID: 15-x384
Trial Phase: Phase I

Trial Sponsor: Washington University, BioMed Valley Discoveries
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Ulixertinib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search